The fourth sentence under the heading "1.1 Use of Patient Registries for Supporting Regulatory Assessments" in "1 Introduction" section should read as below:
For certain products, registry studies may provide postauthorisation data to fulfil regulator-imposed obligations to confirm safety and/or effectiveness, as is the case with the recently authorised chimeric antigen receptor (CAR) T-cell products, tisagenlecleucel and axicabtagene ciloleucel [8, 9] .
In addition, reference 5 should read as below: 5. European Medicines Agency. Patient Registries. https ://www.ema.europ a.eu/en/human -regul atory /post-autho risat ion/patie nt-regis tries . Accessed 25 Aug 2019.
The citation of reference "[6]" should read as " [5] " in Sects. 3, 4 and 6.
The original article can be found online at https ://doi.org/10.1007/ s4026 4-019-00848 -9.
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